靶向FOXM1/CEBPB轴驱动的细胞状态可塑性可破坏肝细胞癌的发育异质性与治疗耐药
该研究利用公共bulk RNA测序和单细胞RNA测序数据及肝细胞分化模型,识别控制肝分化过程中细胞状态转变的关键转录调控因子。研究发现FOXM1/CEBPB轴通过相互抑制形成主决策开关,控制HCC发育异质性动态;抑制FOXM1可恢复肿瘤发育同质性、重新暴露于免疫监视,并设计了靶向肝脏FOXM1的GalNAc偶联化学修饰siRNA,在治疗小鼠模型中显示强效和耐受性。
要点
- FOXM1/CEBPB轴是控制HCC发育异质性的主决策开关。
- 抑制FOXM1可恢复肿瘤发育同质性并重新暴露于免疫监视。
- 靶向肝脏FOXM1的GalNAc-siRNA在治疗小鼠模型中显示强效和耐受性。
核心结论
- FOXM1/CEBPB轴驱动的肿瘤细胞状态可塑性诱导HCC发育异质性和治疗耐药。
- 靶向肝脏FOXM1的RNA干扰疗法显示出进一步临床测试的强潜力。
研究设计与样本
- 对HCC患者公共bulk RNA测序和单细胞RNA测序数据及肝细胞分化模型进行自调控网络分析。
- 使用体外和体内模型研究分子机制并评估治疗潜力。
- 设计GalNAc偶联的化学修饰靶向肝脏FOXM1的小干扰RNA化合物并在治疗小鼠模型中评估。
主要发现
- HCC恶性进展中存在动态细胞状态转变及混乱的发育轨迹。
- 高发育多样性与耐药基因激活和免疫逃逸密切相关,显著影响患者预后。
- FOXM1/CEBPB位于顶端控制发育异质性动态,通过相互抑制并竞争控制下游状态特异性网络形成主决策拨动开关。
- 抑制FOXM1恢复肿瘤发育同质性,重新暴露肿瘤细胞于免疫监视,可能机制为激活IFN-γ信号和抗原呈递。
- 靶向肝脏FOXM1的GalNAc偶联化学修饰siRNA在治疗小鼠模型中显示强效和耐受性。
临床怎么用
- FOXM1/CEBPB轴可作为干预HCC发育异质性和治疗耐药的潜在靶点。
- 靶向肝脏FOXM1的RNAi疗法值得进一步临床测试。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Phenotypic plasticity generates heterogeneous cellular states that span the developmental hierarchy and drive therapeutic resistance in hepatocellular carcinoma (HCC). However, the factors governing this developmental heterogeneity remain unclear, and therapeutic interventions are lacking. METHODS: Autoregulatory network analysis was performed on public datasets of bulk RNA sequencing and single-cell RNA sequencing data from patients with HCC, as well as on our hepatocyte differentiation model, to identify key transcriptional regulators governing the transition of cellular states during hepatic differentiation. In vitro and in vivo models were used to investigate molecular mechanisms and evaluate therapeutic potential. RESULTS: We demonstrate dynamic cell-state transitions with chaotic developmental trajectories in the malignant progression of HCC. High developmental diversity is closely linked to the activation of drug resistance genes and immune evasion, significantly affecting patient prognosis. We identify that the FOXM1/CEBPB axis at the apex controls developmental heterogeneity dynamics. FOXM1/CEBPB form a master decision toggle switch by mutually suppressing each other and competing for control over downstream state-specific networks. Inhibiting FOXM1 restores tumor developmental homogeneity, re-exposing tumor cells to immune surveillance. The likely mechanism is the activation of IFN-γ signaling and antigen presentation. A GalNAc-conjugated, chemically modified small-interfering RNA compound targeting hepatic FOXM1 was designed and showed strong potency and tolerability in therapeutic mouse models. CONCLUSION: Tumor cell-state plasticity driven by the FOXM1/CEBPB axis induces developmental heterogeneity and therapeutic resistance in HCC. RNA interference-based therapies targeting hepatic FOXM1 showed strong potential for further clinical testing. IMPACT AND IMPLICATIONS: Tumor heterogeneity and therapeutic resistance remain major barriers in cancer treatment, largely driven by dynamic transitions across multiple cellular states. This study reveals that the FOXM1/CEBPB axis is a crucial regulator of these hierarchical cellular transitions and plays a key role in sustaining developmental heterogeneity and promoting resistance to therapies. By targeting this axis, we demonstrated the restoration of developmental homogeneity and significant disruption of therapeutic resistance in preclinical models. Furthermore, our findings highlight the strong efficacy of RNAi-based therapeutics directed at hepatic FOXM1, highlighting their promising potential as pioneering small nucleic acid drugs for cancer therapy.
引用
- Zhang XF, Zuo XY, Zhu Y, et al. Targeting cell-state plasticity driven by FOXM1/CEBPB axis disrupts developmental heterogeneity and therapeutic resistance in hepatocellular carcinoma. J Hepatol. 2025. PMID: 41043722. doi:10.1016/j.jhep.2025.09.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。